Can a common heart drug reverse scarring in stiff heart failure?
NCT ID NCT06536309
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the drug sacubitril/valsartan can reduce scarring in the heart muscle of people with a type of heart failure called HFpEF (stiff heart). The trial will enroll 36 adults aged 50 and older with heart failure and a normal pumping function. Participants will receive either the study drug or a comparison drug (valsartan alone) for one year, and heart scarring will be measured using MRI scans.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH PRESERVED EJECTION FRACTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••